J. Robert Dorkin
J. Robert Dorkin
Verified email at mit.edu
Cited by
Cited by
Non-viral vectors for gene-based therapy
H Yin, RL Kanasty, AA Eltoukhy, AJ Vegas, JR Dorkin, DG Anderson
Nature Reviews Genetics 15 (8), 541-555, 2014
Delivery materials for siRNA therapeutics
R Kanasty, JR Dorkin, A Vegas, D Anderson
Nature materials 12 (11), 967-977, 2013
Rational design of cationic lipids for siRNA delivery
SC Semple, A Akinc, J Chen, AP Sandhu, BL Mui, CK Cho, DWY Sah, ...
Nature biotechnology 28 (2), 172-176, 2010
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
A Akinc, A Zumbuehl, M Goldberg, ES Leshchiner, V Busini, N Hossain, ...
Nature biotechnology 26 (5), 561-569, 2008
Lipid-like materials for low-dose, in vivo gene silencing
KT Love, KP Mahon, CG Levins, KA Whitehead, W Querbes, JR Dorkin, ...
Proceedings of the National Academy of Sciences 107 (5), 1864-1869, 2010
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
M Frank-Kamenetsky, A Grefhorst, NN Anderson, TS Racie, B Bramlage, ...
Proceedings of the National Academy of Sciences 105 (33), 11915-11920, 2008
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo
H Yin, CQ Song, JR Dorkin, LJ Zhu, Y Li, Q Wu, A Park, J Yang, S Suresh, ...
Nature biotechnology 34 (3), 328-333, 2016
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
A Akinc, W Querbes, S De, J Qin, M Frank-Kamenetsky, KN Jayaprakash, ...
Molecular Therapy 18 (7), 1357-1364, 2010
Development of lipidoid–siRNA formulations for systemic delivery to the liver
A Akinc, M Goldberg, J Qin, JR Dorkin, C Gamba-Vitalo, M Maier, ...
Molecular Therapy 17 (5), 872-879, 2009
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
Y Dong, KT Love, JR Dorkin, S Sirirungruang, Y Zhang, D Chen, ...
Proceedings of the National Academy of Sciences 111 (11), 3955-3960, 2014
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
KA Whitehead, JR Dorkin, AJ Vegas, PH Chang, O Veiseh, J Matthews, ...
Nature communications 5 (1), 1-10, 2014
Lipid formulation
J Chen, S Ansell, A Akinc, JR Dorkin, X Qin, W Cantley, M Manoharan, ...
US Patent 8,158,601, 2012
Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy
MA Oberli, AM Reichmuth, JR Dorkin, MJ Mitchell, OS Fenton, A Jaklenec, ...
Nano letters 17 (3), 1326-1335, 2017
Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs
KJ Kauffman, JR Dorkin, JH Yang, MW Heartlein, F DeRosa, FF Mir, ...
Nano letters 15 (11), 7300-7306, 2015
Kinome-wide RNAi screen implicates at least 5 host hepatocyte kinases in Plasmodium sporozoite infection
M Prudêncio, CD Rodrigues, M Hannus, C Martin, E Real, LA Gonçalves, ...
PLoS Pathog 4 (11), e1000201, 2008
Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery
OS Fenton, KJ Kauffman, RL McClellan, EA Appel, JR Dorkin, MW Tibbitt, ...
Advanced materials 28 (15), 2939-2943, 2016
In VitroIn Vivo Translation of Lipid Nanoparticles for Hepatocellular siRNA Delivery
KA Whitehead, J Matthews, PH Chang, F Niroui, JR Dorkin, M Severgnini, ...
ACS nano 6 (8), 6922-6929, 2012
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system
F DeRosa, B Guild, S Karve, L Smith, K Love, JR Dorkin, KJ Kauffman, ...
Gene therapy 23 (10), 699-707, 2016
Lipid formulation
J Chen, S Ansell, A Akinc, JR Dorkin, X Qin, W Cantley, M Manoharan, ...
US Patent 8,802,644, 2014
Poly (glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo
Y Dong, JR Dorkin, W Wang, PH Chang, MJ Webber, BC Tang, J Yang, ...
Nano letters 16 (2), 842-848, 2016
The system can't perform the operation now. Try again later.
Articles 1–20